Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

69.31 +1.11 (+1.63%)
Official Closing Price Updated: 4:10 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
34 35 Next >
MINDCURE's "Desire Project" uses MDMA to Treat Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
Photo by Visual Stories || Micheile on Unsplash Mental health is becoming a major concern globally in the wake of the Covid-19 pandemic after historically being an issue... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
OLA and PRIDE Alliance PBRGs teamed up to host an empowering storytelling forum
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
Evotec Expands Neuroscience Collaboration with Bristol Myers
Bristol Myers Squibb & Co (NYSE: BMY) has expanded its neuroscience collaboration with Evotec SE (OTC: EVTCY) to include a new cell type. Related:... 
Via Benzinga
BRISTOL MYERS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
From Kahn Swick & Foti, LLC
Via Business Wire
Markets Boosted
Good news helped stock prices. 
Via Talk Markets
Bristol Myers' TYK2 Inhibitor Disappoints In Mid-Stage Ulcerative Colitis Study
Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from the Phase 2 LATTICE-UC study evaluating deucravacitinib in moderate to severe ulcerative... 
Via Benzinga
Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
From Bristol Myers Squibb
Via Business Wire
Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company
From Entwistle & Cappucci
Via Business Wire
Best Pharmaceutical Stocks To Buy In 2021
The global pharmaceutical market has experienced significant growth in recent years. As of end-2020, the total global pharmaceutical market was valued at about 1.27 trillion U.S. dollars. 
Via Talk Markets
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
Cannabis Movers & Shakers: TOCC, 1933 Industries, Iter Investments, Greenlane
Former Tilray Exec Steven Yoo Named Texas Original Compassionate Cultivation's New CFO Texas medical cannabis provider,&n... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
2 Ridiculously Cheap Growth Stocks to Buy
Though these companies have recorded solid financials of late, investors are overlooking them. 
Via The Motley Fool
Bristol Myers Squibb: Should You Buy the Dip?
Short-term volatility can be a patient, long-term investor's best friend. 
Via The Motley Fool
Bristol Myers Squibb to Hold Investor Event on November 16
From Bristol Myers Squibb
Via Business Wire
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
From Bristol Myers Squibb
Via Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases
From Bristol Myers Squibb
Via Business Wire
Merck Puts Up $11.5 Billion In Acceleron Deal As It Expands Its Cancer Dominance
Merck will buy a company focused, partly, on blood cancer treatment. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Merck Seals Acceleron Pharma Deal For $180/Share: Highlights
Putting all the speculations at bay, Merck & Co Inc (NYSE: MRK) has agreed to acquire Acceleron Pharma Inc (NASDAQ: XLRN) for $180 per share in cash... 
Via Benzinga
A Bit Of A Recovery
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
If the market crashes these companies could be insulated. 
Via The Motley Fool
AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca plc’s (NASDAQ: AZN) Saphnelo (anifrolumab) for systemic lupus... 
Via Benzinga
Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ
The Wall Street Journal reported that Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Acceleron Pharma Inc (NASDAQ: XLRN), citing... 
Via Benzinga
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
Bristol Myers' Two Opdivo Based Regimes Under FDA Review For Esophageal Cancer
The FDA has accepted for review Bristol Myers Squibb & Co Inc's (NYSE: BMY) supplemental marketing applications seeking approval for two Opdivo (nivolumab... 
Via Benzinga
Exposures Product Safety
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is... 
Via Benzinga
Bristol Myers Squibb Matches Employee-led Donations to Community
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.